Chongqing Lummy Pharmaceutical Co Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Chongqing Lummy Pharmaceutical Co Ltd with three other
companies in this sector in China:
Autobio Diagnostics Co Ltd
sales of 980.22 million Chinese Renmimbi [US$148.07 million]
of which 95%
was In vitro diagnosis),
Henan Taloph Pharmaceutical Stock Company Limited
(953.31 million Chinese Renmimbi [US$144.01 million]
of which 68%
was Medicine Manufacturing), and
Zhejiang Shapuaisi Pharmaceutical Co Ltd
(978.73 million Chinese Renmimbi [US$147.85 million]
of which 98%
was Medicine Industry - Chemical pharmaceuti).
During the year ended December of 2016, sales at
Chongqing Lummy Pharmaceutical Co Ltd were 990.18 million Chinese Renmimbi (US$149.58 million).
increase of 2.7%
versus 2015, when the company's sales were 963.85 million Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Chongqing Lummy Pharmaceutical Co Ltd
(and since 2011, sales have increased a total of 85%).
Sales of Chemical Manufacturing saw an increase
that was more than double the company's growth rate: sales were up
7.6% in 2016, from
901.47 million Chinese Renmimbi to 969.84 million Chinese Renmimbi.
Not all segments of Chongqing Lummy Pharmaceutical Co Ltd experienced an increase in sales in 2016:
sales of Other Operations fell 86.7% to 1.15 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Chongqing Lummy Pharmaceutical Co Ltd also experienced decreases in sales in
Chemical Distribution (down 64.3% to 19.23 million Chinese Renmimbi)